Tuesday, April 8, 2014

Adaptive Biotechnologies Scores $105M For Cancer Testing

Seattle-based Adaptive Biotechnologies has raised $105M in a Series D financing round, which all came from Viking Global Investors. The biotechnology company is working on sequencing technology being targeted at cancer immunotherapy. The company said the new funding brings its total capital raised to $120M. Viking gains an observer seat on Adaptive's board as part of the funding. Adaptive Biotechnologies is targeting treatments for cancer, autoimmune disorders, and infectious diseases; the company is initially focused on diagnostic tests for blood cancer. More information »